Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:0080876 |
| Name | IDH-wildtype anaplastic astrocytoma |
| Definition | An anaplastic astrocytoma lacking mutations in IDH1 or IDH2 genes. |
| Source | DiseaseOntology.org |
| Alt Ids | |
| Path | disease disease of cellular proliferation cancer cell type cancer high grade glioma malignant astrocytoma anaplastic astrocytoma IDH-wildtype anaplastic astrocytoma |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04197934 | Phase I | WSD0922 | WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer with Central Nervous System Metastases | Recruiting | USA | 0 |
| NCT05120960 | Phase I | Tepotinib Osimertinib + Tepotinib | A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors | Withdrawn | 0 | |
| NCT05271240 | Phase III | Bevacizumab + Temozolomide Temozolomide | Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM | Recruiting | USA | 0 |
| NCT05938387 | Phase I | CVGBM | Safety and Tolerability of CVGBM in Adults With Newly Diagnosed MGMT-Unmethylated Glioblastoma or Astrocytoma | Active, not recruiting | NLD | DEU | BEL | 0 |
| NCT06558214 | Phase II | Pembrolizumab | OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial (OPTIMUS PRIME) | Recruiting | USA | 0 |